Clinical Trials Logo

Clinical Trial Summary

Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance on the cognitive tasks, with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo.

Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed by pergolide for four weeks.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT00252044
Study type Interventional
Source Bronx VA Medical Center
Contact Emily Hart
Phone 212-241-0441
Email mpgroup@mssm.edu
Status Recruiting
Phase N/A
Start date October 2000

See also
  Status Clinical Trial Phase
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Terminated NCT00353379 - Pharmacology of Cognition in Schizotypal Personality Disorder Phase 4
Recruiting NCT05710926 - Evolutionary Systems Therapy for Schizotypy N/A
Completed NCT00158028 - Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder N/A
Completed NCT02800681 - Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
Completed NCT02524899 - CRT-Guanfacine for SPD Phase 2
Recruiting NCT01466205 - Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Phase 2
Completed NCT02535156 - Schizotypal Personality Disorder Risperidone Phase 1/Phase 2
Completed NCT04764708 - Compassion and Metacognition in Schizotypal Personality N/A
Completed NCT02507206 - A D1 Agonist For Working Memory Phase 2